1 Intrahepatic transcriptomics differentiate advanced fibrosis and clinical outcomes

2 in adults with the Fontan circulation

- 3 Katia Bravo-Jaimes, MD^{1, 2}; Xiuju Wu, MD, PhD³; Leigh C Reardon, MD^{2, 4}; Gentian
- 4 Lluri, MD, PhD^{2, 3}; Jeannette P Lin, MD^{2, 3}; Jeremy P Moore, MD, MS^{2, 4}; Glen Van
- 5 Arsdell, MD^{2, 3}; Reshma Biniwale, MD; Ming-Sing Si, MD, PhD; Bita V Naini, MD⁵;
- 6 Robert Venick, MD⁶; Sammy Saab, MD, MPH⁶; Christopher L Wray, MD⁷; Reid Ponder²;
- 7 Carl Rosenthal⁸; Alexandra Klomhaus, MS, PhD⁹; Kristina I Böstrom, MD, PhD³; Jamil A
- 8 Aboulhosn, MD^{2,3}; Fady M Kaldas, MD⁸
- 9 ¹ Department of Cardiovascular Diseases. Mayo Clinic Jacksonville Florida
- ² Ahmanson/UCLA Adult Congenital Heart Disease Center. University of California, Los
- 11 Angeles
- ³ Division of Cardiology. Department of Medicine. University of California, Los Angeles
- ⁴ Department of Pediatric Cardiology. University of California, Los Angeles Mattel
- 14 Children's Hospital
- ⁵ Department of Pathology and Lab Services. University of California, Los Angeles
- ⁶ Department of Gastroenterology, Hepatology and Nutrition. University of California,
- 17 Los Angeles Mattel Children's Hospital
- ⁷ Department of Anesthesiology. University of California, Los Angeles.
- ⁸ Dumont-UCLA Liver Transplant Center. Department of Surgery. University of
 California, Los Angeles
- ⁹ Department of Medicine Statistics Core. David Geffen School of Medicine. University
- 22 of California, Los Angeles
- 23 Word count: 2378

- 24 Sources of funding: Adult Congenital Heart Association Research Grant 2021 (K.B.J.),
- 25 NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant
- 26 Number UL1TR001881 (A.K.), NIH/NHLBI Grant Number HL81397 (K.I.B.), NIH/NHLBI
- 27 Grant Number HL154548 (K.I.B.). Streisand/American Heart Association Endowed
- 28 Chair in Cardiology (J.A.H.). Kelly Lee Tarantello Endowed Chair in Integrative Liver
- 29 Transplantation (F.M.K.).
- 30
- 31 **Disclosures:** The authors declare no conflicts of interest.
- 32
- 33 Corresponding author:
- 34 Fady M Kaldas, MD
- 35 Dumont-UCLA Liver Transplant Center. Department of Surgery. David Geffen School of
- 36 Medicine at UCLA
- 37 757 Westwood Plaza, Suite 8501, Los Angeles, CA 90095, USA.
- 38 Email: FKaldas@mednet.ucla.edu

39 ABSTRACT

40 Background

The molecular mechanisms underlying Fontan associated liver disease (FALD) remain largely unknown. We aimed to assess intrahepatic transcriptomic differences among patients with FALD according to the degree of liver fibrosis and clinical outcomes.

44 Methods

This retrospective cohort study included adults with the Fontan circulation at the 45 Ahmanson/UCLA Adult Congenital Heart Disease Center. Clinical, laboratory, imaging 46 47 and hemodynamic data prior to the liver biopsy were extracted from medical records. Patients were classified into early (F1-F2) or advanced fibrosis (F3-F4). RNA was 48 49 isolated from formalin-fixed paraffin embedded liver biopsy samples; RNA libraries were 50 constructed using rRNA depletion method and sequencing was performed on Illumina Novaseq 6000. Differential gene expression and gene ontology analyses were carried 51 52 out using DESeg2 and Metascape. Medical records were comprehensively reviewed for 53 a composite clinical outcome which included decompensated cirrhosis, hepatocellular 54 carcinoma, liver transplantation, protein-losing enteropathy, chronic kidney disease 55 stage 4 or higher, or death.

56 **Results**

57 Patients with advanced fibrosis had higher serum BNP levels and Fontan, mean 58 pulmonary artery and capillary wedge pressures. The composite clinical outcome was 59 present in 23 patients (22%) and was predicted by age at Fontan, right ventricular 60 morphology and presence of aortopulmonary collaterals on multivariable analysis. 61 Samples with advanced fibrosis had 228 up-regulated genes compared to early fibrosis. Samples with the composite clinical outcome had 894 up-regulated genes compared to those without it. A total of 136 up-regulated genes were identified in both comparisons and these genes were enriched in cellular response to cytokine stimulus, response to oxidative stress, VEGFA-VEGFR2 signaling pathway, TGF-beta signaling pathway, and vasculature development.

67 Conclusions

68 Patients with FALD and advanced liver fibrosis or the composite clinical outcome exhibit

69 up-regulated genes including pathways related to inflammation, congestion, and

angiogenesis. This adds further insight into FALD pathophysiology.

71 KEYWORDS: single ventricle, liver fibrosis, transcriptomics, Fontan-associated liver
 72 disease, Fontan outcomes

73 Patients with a functional single ventricle represent a population with highly complex 74 anatomy, physiology, and management challenges. Since its first description in 1971, the Fontan operation has been performed for palliation of single ventricle physiology¹. 75 76 Several evolutionary modifications have been made to improve long-term outcomes, but 77 short-and long-term complications including Fontan-associated liver disease (FALD)², continue to occur after Fontan palliation. Preliminary studies have demonstrated that 78 hepatic fibrosis develops early after the Fontan palliation³ and will be present in virtually 79 all patients²⁻⁴, depending mostly on duration of Fontan physiology rather than 80 hemodynamics^{4,5}. Decompensated cirrhosis will only be apparent in some patients and 81 a minority will develop hepatocellular carcinoma⁵. The pathophysiology of FALD 82 includes chronic passive congestion due to elevated systemic venous pressures ^{6,7}, as 83 84 well as chronic low cardiac output. This physiology results in decreased oxygen delivery to centrilobular cells, zone 3 hepatocytes atrophy, sinusoidal fibrosis, eventual bridging 85 fibrosis and finally cardiac cirrhosis^{8,9}. 86

With >70,000 post-Fontan patients worldwide now reaching adulthood², there is a need 87 to better characterize the molecular pathways underlying FALD. We assessed 88 intrahepatic gene expression profiles in adults with the Fontan circulation in comparison 89 with donor controls to test the hypotheses that (1) despite clinical heterogeneity, 90 91 patients with the Fontan circulation and advanced fibrosis exhibit a distinctive gene 92 transcriptome that contrasts with that of early fibrosis and controls; (2) these differences 93 involve enriched pathways related to angiogenesis; and (3) molecular phenotyping can identify Fontan subgroups that exhibit distinct clinical features and prognosis. 94

96 METHODS

97 Fontan study population

The Fontan patient group consisted of adults (>= 18 years old) who have had at least 98 99 two visits at the Ahmanson/UCLA Adult Congenital Heart Disease Center between 100 January 2005 and December 2021 and had tissue available from at least one liver 101 biopsy. The study was approved by the UCLA Institutional Review Board. Baseline 102 clinical, laboratory, imaging and hemodynamic information were extracted from medical 103 records and the results closest to the date of liver biopsy within a 1-year period (6 104 months before and after the liver biopsy) were recorded. These variables included age, sex, height, weight, body mass index (BMI), race/ethnicity, cardiac anatomy, genetic 105 106 syndromes, age at Fontan, cardiac medications (beta-blockers, antiplatelets, 107 anticoagulants, loop diuretics, renin-angiotensin-aldosterone system inhibitors, 108 phosphodiesterase 5 inhibitors, endothelin receptor antagonists, antiarrhythmics), 109 diabetes, hypertension, obesity (BMI >30), hepatitis C, alcohol use, arrhythmias, NYHA 110 class, single ventricle systolic function and atrioventricular valve regurgitation 111 (echocardiographic or by cardiac magnetic resonance), creatinine, platelet count, 112 hemoglobin, AST, ALT, GGT, INR, AFP, total bilirubin, BNP, liver ultrasound, MRI and 113 CT characteristics, exercise-induced desaturation, peak VO2, VE/VCO2, high exercise capacity (>80% age, sex matched peak VO2)¹⁰, low exercise capacity (<50% age, sex 114 matched peak VO2)¹⁰, Fontan pressures, pulmonary artery pressures, pulmonary 115 116 capillary wedge pressures, single ventricle end-diastolic pressure, Qs, pulmonary 117 vascular resistance (PVR), PVR index (PVRi), systemic vascular resistance (SVR), SVR 118 index (SVRi), Fontan pathway obstruction (angiographic evidence of stenosis along the

Fontan pathway with at least 1 mmHg gradient)¹⁰, diastolic dysfunction (single ventricle end-diastolic pressure or pulmonary capillary wedge pressure >= 12 mmHg at baseline or >= 15 mmHg after volume or contrast load)¹⁰, elevated PVR (PVRi >= 2 WU*m2)¹⁰, aortopulmonary and venous-venous collaterals (assessed by angiography).

123 Liver tissue procurement and processing

Archived formalin-fixed paraffin embedded (FFPE) liver tissue from patients with the Fontan circulation who have had liver biopsies were processed by the Translational Pathology Core Laboratory. Slides were independently interpreted by two liver pathologists and METAVIR scores were determined by consensus. Advanced liver fibrosis was defined as those having METAVIR F3-F4 fibrosis on liver biopsy. Normal liver tissue and post-liver transplant biopsy tissue were used as controls.

130 RNA preparation and sequencing

131 Five to six 10 µM sections from each FFPE tissue block were used for RNA extraction. 132 Total RNA was isolated from the liver sections using RNeasy FFPE kit (Qiagen, Cat. 133 No. 73504). RNA samples with $DV200 \ge 30\%$ were processed for library construction 134 using rRNA depletion methods (Roche, KAPA RNA HyperPrep Kit w/ Ribo Erase, KK8561). Sequencing was performed using Illumina Novaseq 6000 platform (2x100bp) 135 136 to the depth of 28-110 million reads per library at UCLA Technology Center for 137 Genomics & Bioinformatics. The FASTQ raw reads were mapped using Spliced Transcripts Alignment to a Reference (STAR, version 2.7.10a)¹¹ to the human reference 138 genome GRCh38 with default parameters. The counts for each gene were generated 139 140 using -quantMode GeneCounts function along the STAR alignment.

142 Differential gene expression analyses

143 Transcripts were first quality filtered to exclude the genes with a mean read count < 5 in 144 each sample. Transcripts without gene annotation were also excluded using R package 145 biomaRt. Data normalization and differential expression analyses were carried out using R package DESeq2 (version 1.38.1)¹¹. After estimation of size factors and dispersion, 146 the likelihood ratio test (LRT) with negative binomial generalized linear model (NB GLM) 147 was used for fitting. Sequencing depth normalized gene counts were obtained from 148 149 DESeqDataSet. Differentially expressed genes (DEGs) were defined using the 5% false discovery rate (Benjamini-Hochberg method) threshold and two-fold change for 150 151 significance. To minimize the possible false discoveries, DESeg function were performed again following permutations on the variables of fibrosis or composite clinical 152 153 outcome. The genes identified in the differential test after permutations were filtered out.

154 Gene ontology and gene-disease association analyses

Gene ontology and gene-disease association (DisGeNet) enrichment analyses were performed using Metascape platform¹². The DisGeNET platform integrates information of human gene-disease associations from various repositories^{13,14}.

158 Statistical analysis of clinical variables

159 Continuous and categorical data were reported as median (interquartile range) and 160 number (percentage), respectively. Between-group differences in the baseline variables 161 described above were examined using Kruskal-Wallis or Pearson chi-square (or 162 Fisher's exact) tests as appropriate. Variables found to significantly (p<0.05) differ 163 between the groups were used in covariate adjusted models. A composite clinical 164 outcome included decompensated cirrhosis (ascites requiring paracentesis, esophageal

variceal bleeding, or hepatic encephalopathy), hepatocellular carcinoma, need for liver transplantation, protein-losing enteropathy, chronic kidney disease stage 4 or higher, or death. An unadjusted cumulative incidence function and Gray's Test, stratified by early vs advanced fibrosis was used to compare time to event relative to the date of Fontan between the two groups. A multivariable Cox proportional hazards model was built using covariates that were associated in univariate analysis as well as those considered clinically meaningful.

172 Data availability

173 RNA sequencing raw data and normalized gene counts can be requested to the174 corresponding author upon reasonable request.

176 **RESULTS**

177 Baseline characteristics according to degree of fibrosis

178 Of 130 adults with the Fontan circulation who had 152 liver biopsies (20 patients had 2 179 liver biopsies and 2 had 3 liver biopsies), 106 patients with 112 adequate RNA quality 180 samples were included. Fifty-five (51.8%) were women, 71 (66.9%) were white and 29 181 (27.4%) were Hispanic. Fifteen patients (14.2%) had no fibrosis, 40 (37.7%) had early 182 fibrosis (F1 in 19 and F2 in 31) and 45 (48.1%) had advanced fibrosis (F3 in 31 and F4 183 in 14) (Supplemental figure 1). Baseline characteristics are detailed in Table 1. Though 184 aortopulmonary collaterals were identified all groups, those without fibrosis were more likely to have a ortopulmonary collaterals (46.7% without fibrosis, 10.0% with early 185 186 fibrosis, 26.8% with advanced fibrosis, p=0.0332). Higher SVRi was seen in the group 187 without fibrosis [25.7 WU·m2 (9.2) without fibrosis, 19.5 WU·m2 (11.3) with early 188 fibrosis, 18.1 WU·m2 (9.4) with advanced fibrosis, p=0.014]. Those with advanced fibrosis were more likely to be on PDE-5 inhibitors (6.7% without fibrosis, 38.0% with 189 190 early fibrosis, 43.9% with advanced fibrosis, p=0.033), have diastolic dysfunction 191 (40.0% without fibrosis, 48.0% with early fibrosis, 70.7% with advanced fibrosis, p=0.017) and higher BNP [44 pg/mL (46) without fibrosis, 47 pg/mL (91) with early 192 193 fibrosis, 95 pg/mL (130) with advanced fibrosis, p=0.016)]. Similarly, they also had a 194 higher VE/VCO2 slope [(27.1 (6) without fibrosis, 27.7 (5.8) with early fibrosis, 30.9 (6.4) 195 with advanced fibrosis, p=0.009], Fontan [14.0 mmHg (5.0) without fibrosis, 14.5 mmHg 196 (3.0) with early fibrosis, 17.0 mmHg (6.0) with advanced fibrosis, p<0.001), mean 197 pulmonary artery [13.5 mmHg (5.0) without fibrosis, 14.0 mmHg (3.0) with early 198 fibrosis, 17.0 mmHg (5.0) with advanced fibrosis, p<0.001), and pulmonary capillary

wedge [10.0 mmHg (4.0) without fibrosis, 10.0 mmHg (4.0) with early fibrosis, 12.0
mmHg (5.0) with advanced fibrosis, p=0.005) pressures.

201 Composite clinical outcome and associated factors

202 Outcomes among patients with the Fontan circulation according to degree of liver 203 fibrosis are found in Table 2. Those with advanced liver fibrosis on biopsy were more 204 likely to experience the composite clinical outcome [0, (0%)] without fibrosis, 8 (16.0 %) 205 with early fibrosis and 15 (36.6%) with advanced fibrosis, p=0.005] (Figure 1). None of 206 the individual components of the composite outcome was significantly associated with 207 advanced fibrosis. In a multivariable Cox proportional hazards model (Table 3) 208 controlling for age at Fontan, age at liver biopsy, right ventricular morphology, Fontan 209 pressure, pulmonary capillary wedge pressure, VE/VCO2 slope, diastolic dysfunction, 210 and aortopulmonary collaterals, there was no difference in the risk of the composite 211 clinical outcome between advanced or early fibrosis. In this multivariable model, there 212 were differences in the risk of the composite clinical outcome based on age at Fontan 213 [HR=1.42 (SE 0.18); p=0.045], right ventricular morphology [HR=26.01 (SE 1.53); 214 p=0.033], and presence of aortopulmonary collaterals [HR=122.77 (SE 1.63); p=0.003].

215 FALD has distinct mRNA expression profiles according to degree of fibrosis and

216 composite clinical outcome

Liver samples from patients with advanced fibrosis had 231 DEGs (228 up-regulated) compared to those with early fibrosis (Figure 2A). Liver samples from patients with the composite clinical outcome had 906 DEGs (894 up-regulated) compared to those without it (Figure 2B). A total of 136 DEGs were identified in both comparisons and they were enriched in various cellular responses and signaling pathways, including response 222 to wounding, extracellular matrix organization, regulation of cell adhesion, IL-18, MAPK 223 and TGF-beta signaling pathways, vasculature development and angiogenesis (Figure 224 3A). Significant correlations of these 136 DEGs were found with various diseases from 225 DisGeNET database, including idiopathic pulmonary arterial hypertension, lung 226 diseases, cardiac fibrosis, vascular diseases, and endothelial dysfunction (Figure 3B). The distribution of specific DEGs involved in FALD pathophysiology are shown 227 228 according to the degree of fibrosis (Figure 4) and presence or absence of the clinical 229 outcome (Figure 5).

230

231 **DISCUSSION**

In this first broad analysis of gene expression in liver tissue from a retrospectively 232 identified cohort of patients with FALD, we reveal several important findings. First, 233 234 patients with FALD and advanced fibrosis have a distinct transcriptome versus those 235 with early fibrosis and controls. Second, patients with FALD and advanced fibrosis are 236 more likely to experience the composite clinical outcome, but this is mediated by age at 237 Fontan, right ventricular morphology and presence of aortopulmonary collaterals. Third, 238 patients with FALD and the composite clinical outcome have a distinct transcriptome 239 compared to those without the composite clinical outcome. Fourth, we identified 240 overlapping DEGs between those with advanced fibrosis as well as the composite 241 clinical outcome, and identified pathways related to pro-inflammatory responses and 242 increased oxidative stress (HSPB1, IRF1, SOCS3, and NFKB2), impaired vascular endothelial function (HSPA1A, HSPA1B, ND5, ND6, NR4A2, SOD3, KLF2), enriched 243 244 angiogenesis and vasculature development (RHOB, COL1A1, NR4A1, NOTCH3,

SERPINE1), TGF-beta signaling pathways, etc. These findings are important given that an inflammatory infiltrate on liver biopsies was not found, and we excluded samples with active hepatocellular carcinoma. These results expand our insights into FALD pathophysiology and show potential candidate genes that could serve as biomarkers of adverse outcomes.

250

251 Out of all the overlapping DEGs identified in our study, COL1A1 RASD1, CHI3L1, 252 MTRNR2, MUC5B, SLCO4A1, SOD3, WNK2 have been previously described in transcriptomic profiling of obesity-related nonalcoholic steatohepatitis¹⁵. Our findings 253 demonstrate that angiogenesis may be particularly important in FALD. This complex, 254 dynamic and growth factor dependent process leading to the formation of new blood 255 256 vessels from preexisting ones, is strongly associated with scar formation and sinusoidal remodeling in chronic liver diseases¹⁰. Several genes are involved in this process 257 including VEGF and ANGPT2¹⁶. High serum angiopoietin-2 levels (protein expressed 258 from ANGPT2) have been associated with liver cirrhosis and hepatocellular carcinoma 259 among samples from nonalcoholic steatohepatitis¹⁷, and several studies are evaluating 260 this as a potential therapeutic target¹⁸⁻²⁰. In a cohort study involving patients with the 261 Fontan circulation, angiopoietin-2 levels were found to be significantly higher in patients 262 with active or recent arrhythmias²¹. Although we did not find ANGPT2 as one of our 263 overlapping genes, we identified VEGFA-VEGFR2 signaling pathway, which is the 264 major pathway that activates angiogenesis. 265

266 Our study had several strengths, including a highly diverse and phenotypically 267 characterized cohort that had longitudinal care at a large ACHD referral center with

medRxiv preprint doi: https://doi.org/10.1101/2023.06.05.23290997; this version posted June 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

268 expertise in combined heart and liver transplantation, as well as achieving more than 269 80% high-guality RNA extraction from FFPE liver biopsies. Moreover, the patients had 270 undergone cardiac catheterization in a standard fashion, limiting the heterogeneity of 271 hemodynamic measurements. Despite this, several limitations were encountered. First, 272 intrahepatic gene expression profiles are largely driven by the effect of parenchymal cells, and this represents a limitation when analyzing bulk transcriptomics. Several 273 274 recent discoveries in the molecular biology of liver cirrhosis (from non-cardiac causes) 275 have highlighted the important role that non-parenchymal liver cells (immune, 276 endothelial, and mesenchymal cells) play in its development. Gene expression profiles 277 of non-parenchymal cells are underrepresented in the whole tissue liver RNA-seq data. Other methods such as single-cell RNA sequencing or digital spatial profiling²² may be 278 279 helpful identifying the gatekeepers of advanced liver fibrosis in FALD. Second, the assessment of aortopulmonary collaterals was not systematically performed in all 280 281 patients unless the patients presented for organ transplantation, and this might 282 influence our univariate as well as multivariable Cox proportional hazards results. Third, 283 small cohort size could have influenced the significance of our results.

284 CONCLUSIONS

Patients with Fontan-associated liver disease exhibit transcriptomic differences according to the degree of fibrosis and the presence of the clinical composite outcome. These genes are involved in pathways related to inflammation, congestion, and angiogenesis.

289

290 SOURCES OF FUNDING

Dr. Bravo-Jaimes was supported by the Adult Congenital Heart Association Research Grant 2021. Dr. Klomhaus was supported by the NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881. Dr. Bostrom was supported by NIH/NHLBI Grant Numbers HL81397 and HL154548. Dr. Aboulhosn was supported by the Streisand/American Heart Association Endowed Chair in Cardiology. Dr. Kaldas was supported by the Kelly Lee Tarantello Endowed Chair in Integrative Liver Transplantation.

298

299 **DISCLOSURES**

300 The authors declare no conflicts of interest.

302 **TABLES**

- 303 Table 1. Baseline characteristics of adults with the Fontan circulation according to the
- degree of liver fibrosis.

	No fibrosis	Early	Advance	p value
	n=15	fibrosis	d fibrosis	
		n=50	n=41	
Left systemic ventricle morphology, n (%)	8 (53.3)	35 (70.0)	20 (48.8)	0.078
Age at Fontan (median, IQR)	4.0 (6.0)	5.0 (7.0)	4.0 (5.0)	0.722
Type of Fontan, n (%)				0.363
Atriopulmonary	3 (20.0)	19 (38.0)	12 (29.3)	
Bjork	0 (0.0)	1 (2.0)	1 (2.4)	
Extracardiac	4 (26.7)	5 (10.0)	11 (26.8)	
Lateral tunnel (Intra-atrial included here)	8 (53.3)	23 (46.0)	14 (34.2)	
Other	0 (0.0)	2 (4.0)	3 (7.3)	
Fenestration, n % (patients with available data n=93)	5 (38.5)	12 (27.9)	16 (43.2)	0.350

Fenestration closure, n %				
(patients with available	3 (60.0)	7 (63.6)	12 (85.7)	0.353
data n=30)				
Fontan conversion, n %	2 (13.3)	10 (20.0)	15 (36.6)	0.099
Heterotaxy, n %	1 (6.7)	5 (10.0)	7 (17.1)	0.459
Diabetes, n %	0 (0.0)	2 (4.0)	4 (9.8)	0.428
Hypertension, n %	1 (6.7)	3 (6.0)	5 (12.2)	0.712
Hepatitis C, n %	0 (0.0)	2 (4.0)	3 (7.3)	0.693
Obesity, n %	1 (6.7)	8 (16.0)	6 (14.6)	0.752
BMI, median (IQR)	22.7 (5.7)	23.8 (7.6)	24.2 (7.3)	0.957
Hemidiaphragm paresis,	0 (0.0)	1 (2.0)	2 (4.9)	0.735
n (%)				
Smoking, n (%)	1 (6.7)	3 (6.0)	3 (7.3)	1.000
Alcohol, n (%)	8 (53.3)	18 (36.0)	13 (31.7)	0.327
Drugs, n (%)	4 (26.7)	8 (16.0)	7 (17.1)	0.630
Prior thromboembolism,	1 (6.7)	14 (28.0)	10 (24.4)	0.218
n (%)				
Protein losing	0 (0.0)	4 (8.0)	5 (12.2)	0.402
enteropathy, n (%)				

Arrhythmia, n (%)	6 (40.0)	34 (68.0)	25 (61.0)	0.148
Pacemaker, n (%)	4 (26.7)	19 (38.0)	20 (48.8)	0.286
Defibrillator, n (%)	1 (6.7)	1 (2.0)	3 (7.3)	0.352
NYHA class, n (%)				0.064
I	12 (80.0)	26 (52.0)	15 (36.6)	
11	3 (20.0)	17 (34.0)	21 (51.2)	
	0 (0.0)	5 (10.0)	3 (7.3)	
IV	0 (0.0)	0 (0.0)	2 (4.9)	
Betablockers, n (%)	8 (53.3)	24 (48.0)	18 (43.9)	0.811
PDE-5 inhibitors, n (%)	1 (6.7)	19 (38.0)	18 (43.9)	0.033
ERAs, n (%)	1 (6.7)	2 (4.0)	2 (4.9)	0.841
Antiplatelets, n (%)	9 (60.0)	25 (50.0)	23 (56.1)	0.737
Anticoagulants, n (%)	4 (26.7)	27 (54.0)	19 (46.3)	0.176
Loop diuretics, n (%)	5 (33.3)	28 (56.0)	25 (61.0)	0.178
ACE inhibitors, n (%)	9 (60.0)	23 (46.0)	19 (46.3)	0.610
ARB, n (%)	1 (6.7)	6 (12.0)	2 (4.9)	0.516
Aldosterone antagonists, n (%)	3 (20.0)	17 (34.0)	21 (51.2)	0.068

Digoxin, n (%)	3 (20.0)	9 (18.0)	10 (24.4)	0.754
Other antiarrhythmics, n (%)	2 (13.3)	16 (32.0)	8 (19.5)	0.214
Creatinine (median, IQR)	0.8 (0.2)	0.8 (0.2)	0.9 (0.4)	0.223
Platelets (median, IQR)	170.0 (53.0)	158.0 (82.0)	134.5 (60.0)	0.106
Hemoglobin (median, IQR)	15.5 (4.0)	15.1 (2.9)	15.1 (2.7)	0.692
Albumin (median, IQR)	4.7 (0.6)	4.7 (0.7)	4.4 (1.0)	0.057
INR (median, IQR)	1.2 (0.0)	1.2 (0.3)	1.3 (0.4)	0.230
AFP (median, IQR)	3.0 (8.0)	2.0 (1.0)	3.0 (2.0)	0.489
BNP (median, IQR)	44.0 (46.0)	47.0 (91.0)	95.0 (130.0)	0.016
Systemic ventricle function, n (%)				0.181
Normal or mildly reduced	12 (80.0)	45 (90.0)	31 (75.6)	
Moderately or severely reduced	3 (20.0)	5 (10.0)	10 (24.4)	
AVV regurgitation, n (%)				0.161

None, trace or mild	13 (86.7)	36 (72.0)	25 (61.0)	
Moderate or severe	2 (13.3)	14 (28.0)	16 (39.0)	
Liver US characteristics, n (%) (patients with available data n=88)				
Nodular contour	5 (35.7)	24 (63.2.0)	24 (66.7)	0.118
Splenomegaly	4 (28.6)	11 (29.0)	13 (36.1)	0.772
Abdominal collateral vessels	1 (7.1)	0 (0.0)	1 (2.8)	0.155
Ascites	0 (0.0)	7 (18.4)	8 (22.2)	0.165
Elevated liver stiffness	4 (28.6)	14 (36.8)	14 (38.9)	0.790
Liver mass	0 (0.0)	3 (7.9)	1 (2.8)	0.514
Liver MRI characteristics, n (%) (patients with available data n=25)				
Nodular contour	5 (100.0)	9 (64.3)	4 (66.7)	0.405
Splenomegaly	1 (20.0)	4 (28.6)	3 (50.0)	0.611
Ascites	0 (0.0)	2 (14.3)	2 (33.3)	0.468
Abdominal collateral	0 (0.0)	1 (7.1)	1 (16.7)	0.697

vessels				
Elevated stiffness	0 (0.0)	0 (0.0)	2 (33.3)	0.083
Liver mass	0 (0.0)	0 (0.0)	2 (33.3)	0.083
Liver CT characteristics,				
n (%) (patients with				
available data n=54)				
Nodular contour	4 (66.7)	21 (80.8)	20 (90.9)	0.275
Splenomegaly	4 (66.7)	8 (30.8)	15 (68.2)	0.032
Abdominal collateral vessels	2 (33.3)	6 (23.1)	10 (45.5)	0.270
Ascites	3 (50.0)	11 (42.3)	11 (50.0)	0.926
Liver mass	0 (0.0)	3 (11.5)	2 (9.1)	1.000
Baseline O2Sat (median, IQR) (patients with available data n=92)	93.0 (3.0)	92.5 (6.0)	92.0 (6.0)	0.655
Peak O2Sat (median, IQR)	92.0 (5.0)	89.0 (8.0)	90.0 (7.0)	0.616
Exercise-induced desaturation (peak O2 – baseline O2) (median, IQR)	2.0 (2.0)	3.0 (5.0)	2.0 (3.0)	0.576

Peak VO2 (median, IQR)	61.0 (17.0)	59.0 (22.0)	55.5 (26.0)	0.645
VE/VCO2 slope (median, IQR)	27.1 (6.0)	27.7 (5.8)	30.9 (6.4)	0.009
High exercise capacity, n (%)	2 (13.3)	6 (12.0)	7 (17.1)	n/a
Low exercise capacity, n (%)	2 (13.3)	9 (18.0)	13 (31.7)	n/a
Fontan pressure, median (IQR)	14.0 (5.0)	14.5 (3.0)	17.0 (6.0)	<.001
Mean PAP, median (IQR)	13.5 (5.0)	14.0 (3.0)	17.0 (5.0)	<.001
Pulmonary capillary wedge pressure, median (IQR)	10.0 (4.0)	10.0 (4.0)	12.0 (5.0)	0.005
Single ventricle end- diastolic pressure, median (IQR)	10.0 (5.0)	10.0 (5.5)	10.0 (3.0)	0.609
Qs, median (IQR)	4.3 (1.4)	4.5 (1.9)	5.0 (2.6)	0.273
Qs index, median (IQR)	2.5 (0.7)	2.7 (1.1)	2.7 (1.6)	0.153
PVR, median (IQR)	0.9 (0.4)	0.9 (0.7)	1.1 (0.8)	0.485

PVRi, median (IQR)	1.7 (0.8)	1.6 (1.3)	2.0 (1.5)	0.674
SVR, median (IQR)	13.0 (4.3)	11.3 (7.3)	10.2 (5.6)	0.067
SVRi, median (IQR)	25.7 (9.2)	19.5 (11.3)	18.1 (9.4)	0.014
Fontan pathway obstruction, n (%)	0 (0.0)	7 (14.0)	8 (19.5)	0.115
Diastolic dysfunction, n (%)	6 (40.0)	24 (48.0)	29 (70.7)	0.017
Elevated PVR, n (%)	4 (26.7)	18 (36.0)	17 (41.5)	0.290
Aortopulmonary collaterals, n (%)	7 (46.7)	5 (10.0)	11 (26.8)	0.006
Venous-venous collaterals, n (%)	8 (53.3)	26 (52.0)	18 (43.9)	0.698

305 *p-values from chi-square test for independence (or Fisher's exact test when

306 appropriate) for categorical variables, and Kruskal-Wallis test for continuous variables

307 **p-values do not include missing values on any given variable

308 *** frequencies were calculated among those with available data and not among total N

309 in each column

311 Table 2. Outcomes among patients with the Fontan circulation according to liver biopsy

312 results.

Outcomes	No fibrosis	Early	Advanced	P value
		fibrosis	fibrosis	
Thromboembolism, n (%)	1 (6.7)	1 (2.0)	1 (2.4)	0.527
Arrhythmias, n (%)	4 (26.7)	14 (28.0)	7 (17.0)	0.215
Composite clinical outcome, n (%)	0 (0)	8 (16.0)	15 (36.6)	0.005
Decompensated cirrhosis, n (%)	0 (0)	4 (8.0)	7 (17.1)	0.138
Ascites requiring paracentesis	0 (0)	3 (6.0)	5 (12.2)	0.402
Esophageal variceal bleeding	0 (0)	1 (2.0)	2 (4.9)	0.740
Hepatic encephalopathy	0 (0)	0 (0.0)	0 (0.0)	n/a
Hepatocellular carcinoma, n (%)	0 (0.0)	2 (4.0)	1 (2.4)	1.000
Focal nodular	1 (6.7)	5 (10.0)	5 (12.2)	0.544

hyperplasia, n (%)				
Chronic kidney disease, n (%)	0 (0.0)	1 (2.0)	1 (2.4)	0.115
Fontan circulatory failure, n (%)	1 (6.7)	11 (22.0)	15 (36.6)	0.056
Liver transplant, n (%)	0 (0.0)	5 (10.0)	8 (19.5)	0.109
Heart transplant, n (%)	1 (6.7)	9 (18.0)	13 (31.7)	0.090
Death, n (%)	0 (0.0)	3 (6.0)	3 (7.3)	0.858

313

*Composite clinical outcome of decompensated cirrhosis (ascites requiring
paracentesis, esophageal variceal bleeding, hepatic encephalopathy), hepatocellular
carcinoma, need for liver transplantation, protein-losing enteropathy, chronic kidney
disease stage 4 or higher, or death.

318

320 Table 3. Multivariable Cox proportional hazards model for the composite clinical321 outcome.

Parameter	Hazard Ratio	Standard Error	P value
Age at Fontan	1.42	0.18	0.045
Right ventricular morphology	26.01	1.53	0.033
Fontan pressure	1.68	0.37	0.162
Pulmonary capillary wedge pressure	1.17	0.24	0.517
VE/VCO2 slope	0.97	0.09	0.744
Diastolic dysfunction	0.08	2.00	0.209
Aortopulmonary collaterals	122.77	1.62	0.003
Age at liver biopsy	0.97	0.10	0.752
Advanced fibrosis	0.19	1.22	0.179

322

323

325 FIGURES

Figure 1. Unadjusted cumulative incidence function comparing time to the clinical composite outcome, relative to date of Fontan, between patients with early vs advanced fibrosis.



Figure 2. A. Volcano plot showing 231 DEGs (228 up-regulated) in patients with FALD and advanced fibrosis vs early fibrosis. B. Volcano plot showing 906 DEGs (894 upregulated) in patients with FALD and the clinical composite outcomes vs those without it.



339 Figure 3. A. Gene ontology and pathway enrichment analysis among patients with 340 advanced liver fibrosis. B. Gene disease association enrichment analysis using 136 DEGs and the DisGeNet platform. 341

342

А IL-18 signaling pathway 343 cellular response to cytokine stimulus 344 -LogP MAPK signaling pathway VEGFA-VEGFR2 signaling pathway cellular response to oxidative stress response to reactive oxygen species Signaling by TGF-beta Receptor Complex vasculature development 5.0 2.5 7.5 10.0 0.0 -LogP

10

9 8

7

6

В



345 Figure 4. Violin plot demonstrating the gene count distribution in specific overlapping

NR4A1 COL1A1 NR4A3 TGFB3 1e+06 1e+05 10000 1000 1e+0 1e+04 10 tunoo 1e+03 tunoo 1e+02 count count 100 1e+02 1e+00 1e+01 nor non non early Fibrosis early Fibrosis Fibrosis Fibrosis ADAMTS4 SERPINE1 ADAMTS1 MMP2 1e+05 10000 10000 1e+05 1e+03 100 count count count count 1e+0 100 1e+0 1e+01 1e-01 early Fibrosis early Fibrosis Fibrosis early Fibrosis CHI3L1 SOCS3 FSTL3 IGF2 1e+06 1e+06 10000 1e+0 1000 1e+04 100 1e+02 count count count 1e+02 100 100 1e+00 1e+00 none early Fibrosis advanced none early Fibrosis advanced none early Fibrosis advanced none early Fibrosis advanced HSPB1 JUN IL32 KDM6B 1e+06 1e+05 10000 10000 1000 1000 1e+03 1e+0 count count count count 100 100 10 10 1e+01 1e+02 none early Fibrosis none none early Fibrosis none advanced advanced advanced advanced early Fibrosis Fibrosis

346 genes among patients with FALD according to the degree of liver fibrosis.

Figure 5. Violin plot demonstrating the gene count distribution in specific overlapping 347

genes among patients with FALD according to the presence of the composite outcome. 348



351 **REFERENCES**

- 352 1. Fontan F, Baudet E. Surgical repair of tricuspid atresia. *Thorax.* 1971;26:240-
- 353 248. doi: 10.1136/thx.26.3.240
- 2. Emamaullee J, Zaidi AN, Schiano T, Kahn J, Valentino PL, Hofer RE, Taner T,
- 355 Wald JW, Olthoff KM, Bucuvalas J, et al. Fontan-Associated Liver Disease:
- 356 Screening, Management, and Transplant Considerations. *Circulation*.
- 357 2020;142:591-604. doi: 10.1161/CIRCULATIONAHA.120.045597
- 358 3. Agnoletti G, Ferraro G, Bordese R, Marini D, Gala S, Bergamasco L, Ferroni F,
- 359 Calvo PL, Barletti C, Cisaro F, et al. Fontan circulation causes early, severe liver
- damage. Should we offer patients a tailored strategy? Int J Cardiol. 2016;209:60-
- 361 65. doi: 10.1016/j.ijcard.2016.02.041
- 362 4. Goldberg DJ, Surrey LF, Glatz AC, Dodds K, O'Byrne ML, Lin HC, Fogel M,
- 363 Rome JJ, Rand EB, Russo P, et al. Hepatic Fibrosis Is Universal Following
- 364 Fontan Operation, and Severity is Associated With Time From Surgery: A Liver
- Biopsy and Hemodynamic Study. *J Am Heart Assoc.* 2017;6. doi:
- 366 10.1161/JAHA.116.004809
- 367 5. Khan S, Aziz H, Emamaullee J. Research priorities in Fontan-associated liver
- 368 disease. *Curr Opin Organ Transplant*. 2020;25:489-495. doi:
- 369 10.1097/MOT.00000000000803
- 370 6. Egbe AC, Poterucha JT, Warnes CA, Connolly HM, Baskar S, Ginde S, Clift P,
- 371 Kogon B, Book WM, Walker N, et al. Hepatocellular Carcinoma After Fontan
- 372 Operation: Multicenter Case Series. *Circulation*. 2018;138:746-748. doi:
- 373 10.1161/CIRCULATIONAHA.117.032717

- 374 7. Rychik J, Veldtman G, Rand E, Russo P, Rome JJ, Krok K, Goldberg DJ, Cahill
- 375 AM, Wells RG. The precarious state of the liver after a Fontan operation:
- summary of a multidisciplinary symposium. *Pediatr Cardiol.* 2012;33:1001-1012.
- doi: 10.1007/s00246-012-0315-7
- 8. Keung CY, Zentner D, Gibson RN, Phan DH, Grigg LE, Sood S, Nicoll AJ.
- 379 Fontan-associated liver disease: pathophysiology, investigations, predictors of
- 380 severity and management. *Eur J Gastroenterol Hepatol*. 2019. doi:
- 381 10.1097/MEG.00000000001641
- 382 9. Hilscher MB, Johnson JN, Cetta F, Driscoll DJ, Poterucha JJ, Sanchez W,
- 383 Connolly HM, Kamath PS. Surveillance for liver complications after the Fontan
- 384 procedure. *Congenit Heart Dis.* 2017;12:124-132. doi: 10.1111/chd.12446
- 385 10. Alsaied T, Rathod RH, Aboulhosn JA, Budts W, Anderson JB, Baumgartner H,
- Brown DW, Cordina R, D'Udekem Y, Ginde S, et al. Reaching consensus for
- 387 unified medical language in Fontan care. ESC Heart Fail. 2021;8:3894-3905. doi:
- 388 10.1002/ehf2.13294
- 389 11. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P,
- 390 Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner.
- *Bioinformatics*. 2013;29:15-21. doi: 10.1093/bioinformatics/bts635
- 392 12. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner
- 393 C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis
- 394 of systems-level datasets. *Nat Commun*. 2019;10:1523. doi: 10.1038/s41467-
- 395 019-09234-6

396	13.	Pinero J, Bravo A, C	Queralt-Rosinach N,	Gutierrez-Sacristan A, Deu-Pons J,
-----	-----	----------------------	---------------------	------------------------------------

- 397 Centeno E, Garcia-Garcia J, Sanz F, Furlong LI. DisGeNET: a comprehensive
- 398 platform integrating information on human disease-associated genes and
- 399 variants. *Nucleic Acids Res.* 2017;45:D833-D839. doi: 10.1093/nar/gkw943
- 400 14. Pinero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A, Baron M,
- 401 Sanz F, Furlong LI. DisGeNET: a discovery platform for the dynamical
- 402 exploration of human diseases and their genes. *Database (Oxford)*.
- 403 2015;2015:bav028. doi: 10.1093/database/bav028
- 404 15. Gerhard GS, Legendre C, Still CD, Chu X, Petrick A, DiStefano JK.
- 405 Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals
- 406 a Core Set of Fibrosis-Specific Genes. *J Endocr Soc.* 2018;2:710-726. doi:
- 407 10.1210/js.2018-00122
- 408 16. Bocca C, Novo E, Miglietta A, Parola M. Angiogenesis and Fibrogenesis in
- 409 Chronic Liver Diseases. *Cell Mol Gastroenterol Hepatol.* 2015;1:477-488. doi:
- 410 10.1016/j.jcmgh.2015.06.011
- 411 17. Lefere S, Devisscher L, Geerts A. Angiogenesis in the progression of non412 alcoholic fatty liver disease. *Acta Gastroenterol Belg.* 2020;83:301-307.
- 413 18. Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, Koch I, Pascu
- 414 M, Wiedenmann B, Berg T, et al. Angiopoietin-2 serum levels are elevated in
- 415 patients with liver cirrhosis and hepatocellular carcinoma. *Am J Gastroenterol*.
- 416 2007;102:2471-2481. doi: 10.1111/j.1572-0241.2007.01377.x
- 417 19. Pauta M, Ribera J, Melgar-Lesmes P, Casals G, Rodriguez-Vita J, Reichenbach
- 418 V, Fernandez-Varo G, Morales-Romero B, Bataller R, Michelena J, et al.

419		Overexpression of angiopoietin-2 in rats and patients with liver fibrosis.
420		Therapeutic consequences of its inhibition. <i>Liver Int</i> . 2015;35:1383-1392. doi:
421		10.1111/liv.12505
422	20.	Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S,
423		Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, et al.
424		Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target
425		in Murine Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> . 2019;69:1087-1104. doi:
426		10.1002/hep.30294
427	21.	Shirali AS, Lluri G, Guihard PJ, Conrad MB, Kim H, Pawlikowska L, Bostrom KI,
428		Iruela-Arispe ML, Aboulhosn JA. Angiopoietin-2 predicts morbidity in adults with
429		Fontan physiology. <i>Sci Rep</i> . 2019;9:18328. doi: 10.1038/s41598-019-54776-w
430	22.	Lee J, Kim CM, Cha JH, Park JY, Yu YS, Wang HJ, Sung PS, Jung ES, Bae SH.
431		Multiplexed Digital Spatial Protein Profiling Reveals Distinct Phenotypes of
432		Mononuclear Phagocytes in Livers with Advanced Fibrosis. Cells. 2022;11. doi:
433		10.3390/cells11213387

434 SUPPLEMENTAL FIGURES

435 Supplemental figure 1. Flow diagram of patients and samples included.

